Canada’s Drug Agency (CDA-AMC), the country’s health-technology assessment agency, issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. The recommendation followed reconsideration and is a step toward wider access, although negotiations through the pan-Canadian Pharmaceutical Alliance and subsequent reimbursement decisions by provincial and territorial public drug plans remain outstanding. More than 770,000 people in Canada were estimated to be living with dementia in 2025, with the figure projected to reach 1.7 million by 2050. Leqembi, developed through a strategic research alliance between BioArctic and Eisai, is approved in 53 countries and under regulatory review in six.